Pharmaceuticals, Biotechnology and Life Sciences
Rubraca recommended as a treatment option for BRCA-mutant mCRPC in the second line setting and as a subsequent therapy; if…
Clovis reported a net loss for the first quarter of 2020 of $99.3 million, or ($1.39) per share, compared to the net loss for the first quarter of 2019 which was $86.4 million, or ($1.63) per share. Net loss for the first quarter of 2020 included share-based compensation expense of $13.0 million, compared to $13.6 million for the first quarter of 2019.
The updated data from Clovis’s TRITON2 trial confirm the potential role of rucaparib in treating metastatic castration-resistant prostate cancer
Clovis to acquire rights to discovery program for three additional targets for radionuclide therapy Clovis to pay approximately $12 million…
Updated data from the Phase 2 TRITON2 trial of Rubraca in patients with advanced metastatic castration-resistant prostate cancer (mCRPC) Exploratory…
Quality-adjusted progression free survival (QA-PFS) andquality-adjusted time without cancer related symptoms or toxicity(Q-TWiST) demonstrate the benefit of Rubraca maintenance treatment overplacebo from a patient perspective
Exploratory analyses of ARIEL3 Rubraca data in recurrent ovarian cancer presented in oral plenary and poster sessions Maintenance treatment with…
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to orphan drug Rubraca (rucaparib) to treat women with…